MedTrace Logo

An Integrated Radio-immunological Approach

NCT05267509 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2026-01-23

No results posted yet for this study

Summary

The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leukocytes, especially of myeloid origin, endowed with immunosuppressive function is observed. Aim of this study is to evaluate myeloid cell infiltrate and iron metabolism in tumor-associated macrophages by combining a multimodal MRI imaging technique with immunophenotyping of the tumor microenvironment.

Conditions

  • Glioma, Malignant

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Careggi

    collaborator OTHER

  • Azienda Ospedaliera di Padova

    collaborator OTHER

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Susanna Mandruzzato, PhD · Istituto Oncologico Veneto IOV-IRCCS

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2025-06-30
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05267509 on ClinicalTrials.gov